Institution
Hospital General Universitario Gregorio Marañón
Healthcare•Madrid, Spain•
About: Hospital General Universitario Gregorio Marañón is a healthcare organization based out in Madrid, Spain. It is known for research contribution in the topics: Population & Transplantation. The organization has 11975 authors who have published 12386 publications receiving 244847 citations.
Topics: Population, Transplantation, Myocardial infarction, Intensive care, COPD
Papers published on a yearly basis
Papers
More filters
••
Hospital General Universitario Gregorio Marañón1, University of Melbourne2, National Institutes of Health3, University Medical Center Groningen4, University of Toronto5, London School of Economics and Political Science6, King's College London7, University of Colorado Denver8, University of Maryland, Baltimore9
TL;DR: Promising universal, selective, and indicated preventive mental health strategies that might reduce the incidence of mental health disorders, or shift expected trajectories to less debilitating outcomes are reviewed.
331 citations
••
TL;DR: 3D bioprinting is a suitable technology to generate bioengineered skin for therapeutical and industrial applications in an automatized manner and the generated skin was indistinguishable from bilayered dermo-epidermal equivalents, handmade in the authors' laboratories.
Abstract: Significant progress has been made over the past 25 years in the development of in vitro-engineered substitutes that mimic human skin, either to be used as grafts for the replacement of lost skin, or for the establishment of in vitro human skin models. In this sense, laboratory-grown skin substitutes containing dermal and epidermal components offer a promising approach to skin engineering. In particular, a human plasma-based bilayered skin generated by our group, has been applied successfully to treat burns as well as traumatic and surgical wounds in a large number of patients in Spain. There are some aspects requiring improvements in the production process of this skin; for example, the relatively long time (three weeks) needed to produce the surface required to cover an extensive burn or a large wound, and the necessity to automatize and standardize a process currently performed manually. 3D bioprinting has emerged as a flexible tool in regenerative medicine and it provides a platform to address these challenges. In the present study, we have used this technique to print a human bilayered skin using bioinks containing human plasma as well as primary human fibroblasts and keratinocytes that were obtained from skin biopsies. We were able to generate 100 cm2, a standard P100 tissue culture plate, of printed skin in less than 35 min (including the 30 min required for fibrin gelation). We have analysed the structure and function of the printed skin using histological and immunohistochemical methods, both in 3D in vitro cultures and after long-term transplantation to immunodeficient mice. In both cases, the generated skin was very similar to human skin and, furthermore, it was indistinguishable from bilayered dermo-epidermal equivalents, handmade in our laboratories. These results demonstrate that 3D bioprinting is a suitable technology to generate bioengineered skin for therapeutical and industrial applications in an automatized manner.
330 citations
••
TL;DR: Paediatric Intensive Care, Hopital Universitaire des Enfants, 15 av JJ Crocq, Brussels, Belgium; Great Ormond Street Hospital for Children, London, UK; Zentrum Anaesthesiologie, Rettungsund Intensivmedizin Gottingen; and Imperial College Healthcare NHS Trust.
330 citations
••
Centers for Disease Control and Prevention1, California State Polytechnic University, Pomona2, Hospital General Universitario Gregorio Marañón3, Institute of Tropical Medicine Antwerp4, Médecins Sans Frontières5, Northwick Park Hospital6, Istituto Superiore di Sanità7, Boston Children's Hospital8, University of Nice Sophia Antipolis9, Drugs for Neglected Diseases Initiative10, Banaras Hindu University11, World Health Organization12
TL;DR: Clinical trials and experience demonstrate high efficacy and low toxicity for liposomal amphotericin B (total dose, 20 mg/kg) in immunocompetent patients with VL, and the public health community should work to broaden access to preferential liposome amphoteric in B pricing by public sector VL treatment programs.
Abstract: During the past decade, liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL). The World Health Organization convened a workshop to review current knowledge and to develop guidelines for liposomal amphotericin B use for VL. In Europe, liposomal amphotericin B is widely used to treat VL. In Africa and Asia, the VL disease burden is high and drug access is poor; liposomal amphotericin B is available only through preferential pricing for nonprofit groups in East Africa. Clinical trials and experience demonstrate high efficacy and low toxicity for liposomal amphotericin B (total dose, 20 mg/kg) in immunocompetent patients with VL. Combination trials in areas with antileishmanial drug resistance, and treatment and secondary prophylaxis trials in VL-human immunodeficiency virus-coinfected patients, are important to safeguard the current armamentarium and to optimize regimens. The public health community should work to broaden access to preferential liposomal amphotericin B pricing by public sector VL treatment programs.
328 citations
••
TL;DR: A large series of patients with chronic obstructive pulmonary disease and probable invasive pulmonary aspergillosis (IPA) are described, and the risk factors and incidence of the disease in patients with isolation of Aspergillus from lower respiratory tract samples are described.
323 citations
Authors
Showing all 12014 results
Name | H-index | Papers | Citations |
---|---|---|---|
David H. Adams | 155 | 1613 | 117783 |
Stefanie Dimmeler | 147 | 574 | 81658 |
Stuart J. Pocock | 145 | 684 | 143547 |
M. I. Martínez | 134 | 1251 | 79885 |
Guy A. Rouleau | 129 | 884 | 65892 |
Jose L. Jimenez | 124 | 654 | 64226 |
Antoni Torres | 120 | 1238 | 65049 |
Paul P. Tak | 112 | 591 | 57689 |
Luis A. Diaz | 111 | 596 | 75036 |
Frans Van de Werf | 109 | 747 | 63537 |
José Luis Zamorano | 105 | 695 | 133396 |
Francisco Sánchez-Madrid | 102 | 527 | 43418 |
Francesco Locatelli | 99 | 820 | 42454 |
Roberto M. Lang | 96 | 823 | 56638 |
Carlos Simón | 95 | 589 | 31147 |